A clinical trial to establish the proper diagnosis and therapy of Hypereosinophilic syndrome.

A clinical trial to establish the proper diagnosis and therapy of Hypereosinophilic syndrome. - Efficacy of Imatinib for HES

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008653

Enrollment

Registered

2012-08-15

Start date

2012-08-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypereosinophilic syndrome, chronic eosinophilic leukemia

Interventions

Imatinib administration at the dose of 100mg/day for 4 weeks. Dose escalation up to 400mg/day according to the hematological response.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Diagnosed HES/CEL

Exclusion criteria

Exclusion criteria: 1) Presence of any other active neoplasm 2) Prior anti-leukemic treatment within two weeks. 3) Psychological disorder 4) Hypersensitivity to ingredient of Imatinib 5) Pregnant or nursing women 3) Whom the investigator considered inappropriate to this study

Design outcomes

Primary

Measure	Time frame
Imatinib responsiveness; complete remission(CR) ratio, time to achievement, time to progression.	—

Secondary

Measure	Time frame
1)Organic dysfunction caused by hepereosinophilia 2)Expression levels and stractual changes of F-P fusion mRNA, and mutational analysis in imatinib resistance 3)Adverse effects of Imatinib	—

Countries

Japan

Contacts

Public ContactAkiko Sada

Kobe University Graduate School of Medicine, Division of Hematology,Department of Medicine

akikosad@med.kobe-u.ac.jp078-382-5111(6912)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026